artience and Immuno-Biological Laboratories Sign a Memorandum of Understanding on Business Alliance in Life Sciences

We aim to improve and stabilize the quality of in vitro diagnostics, test reagents, and antibodies by utilizing chemically synthesized additives that replace biologically derived proteins.

artience Co., Ltd. (President and Representative Director Satoru Takashima, Chuo-ku, Tokyo) and Immuno-Biological Laboratories, Co., Ltd.(President and Representative Director Tsutomu Seito, Fujioka City, Gunma Prefecture, hereinafter referred to as IBL) signed a basic agreement on July 1 regarding a business alliance in the life science-related business of materials and reagents for testing and research, as well as in vitro diagnostics.

The life sciences market continues to grow globally due to the growing demand for biopharmaceuticals and the growing importance of in vitro diagnostics in the wake of the pandemic. As a result, reagents for research such as drug discovery screening and gene and antibody testing are becoming more sophisticated, but there are issues such as improving the accuracy of antigen-antibody reactions used in these processes, variations in the quality of biologically derived raw materials, and stability in procurement.

IBL is one of Japan's top antibody manufacturers, developing the business of research reagent kits and in vitro diagnostics for more than 40 years since its founding. We possess advanced technological capabilities in antibody development, and in recent years, we have accelerated our development in overseas markets, where demand is increasing, such as overseas sales accounting for more than 40% of our sales.
artience has identified the biotechnology field as one of its next-generation businesses in its medium-term management plan, and is working to create a business, developing near-infrared fluorescent probes for high-sensitivity imaging and functional polymers for in-vitro diagnostics based on colorants and polymers, which are core materials. In particular, synthetic polymers used in in vitro diagnostics and research reagents have been recognized for their ability to significantly suppress quality variations, which are issues unique to biologically derived raw materials, and for their ability to improve the sensitivity of antigen-antibody reactions.
In this business alliance, IBL's technologies related to antibodies, reagent kits, and in vitro diagnostics will be combined with artience 's polymer materials and chemical synthesis technologies to improve the quality and stabilization of antibodies, and to develop more accurate and stable in-vitro diagnostics and test reagents that do not require bio-derived proteins. We aim to provide original and high-quality products to the whole world.

artience group aims to contribute to the resolution of issues ranging from the early detection of diseases to diagnosis and treatment by providing materials and services that apply material design technologies such as colorants and polymers to the field of life sciences, and to realize a society where people can live fulfilling lives.

Newsroom